Real-world cabazitaxel safety: The Italian early-access program in metastatic castration-resistant prostate cancer

Future Oncology

Volumn 10, Issue 6, 2014, Pages 975-983

  Bracarda, Sergio ^a   Gernone, Angela ^b   Gasparro, Donatello ^c   Marchetti, Paolo ^d   Ronzoni, Monica ^e   Bortolus, Roberto ^f   Fratino, Lucia ^f   Basso, Umberto ^g   Mazzanti, Roberto ^h   Messina, Caterina ⁱ   Tucci, Marcello ^j   Boccardo, Francesco ^k   Cartenì, Giacomo ^l   Pinto, Carmine ^m   Fornarini, Giuseppe ⁿ   Mattioli, Rodolfo ^o   Procopio, Giuseppe ^p   Chiuri, Vincenzo ^q   Scotto, Tiziana ^r   Dondi, Davide ^s   Di Lorenzo, Giuseppe ^t   more..

^a IRCCS POLICLINICO SAN DONATO   (Italy)

^b POLICLINICO   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^g VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^h CAREGGI UNIVERSITY HOSPITAL   (Italy)

ⁱ Pope John XXIII Hospital   (Italy)

^j SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

^l CARDARELLI HOSPITAL   (Italy)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ UNIVERSITY OF GENOA   (Italy)

^o Ospedali Riuniti Marche Nord   (Italy)

^p NATIONAL CANCER INSTITUTE   (Italy)

^q Department of Mental Health   (Italy)

^r Unit of Medical Oncology   (Italy)

^s Medical Affairs Europe   (Italy)

^t UNIVERSITY OF NAPLES FEDERICO II   (Italy)

more..

Author keywords

cabazitaxel; castrate resistant; docetaxel; prostate cancer; safety; taxane

Indexed keywords

CABAZITAXEL; DEXAMETHASONE; DEXCHLORPHENIRAMINE; DIPHENHYDRAMINE; DOCETAXEL; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISOLONE; RANITIDINE; ANTINEOPLASTIC AGENT; TAXOID;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY INTERVENTION; FEBRILE NEUTROPENIA; HEALTH CARE ACCESS; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; VERY ELDERLY; CLINICAL TRIAL; ITALY; METASTASIS; MIDDLE AGED; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; HUMANS; ITALY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TAXOIDS; TREATMENT OUTCOME;

EID: 84903150063     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.13.256     Document Type: Article

References (26)

1. American Cancer Society. Global Cancer Facts and Figures. American Cancer Society, Atlanta, GA, USA (2007
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011
3. Bray F, Lortet-Tieulent J, Ferlay J, Forman D, Auvinen A. Prostate cancer incidence and mortality trends in 37 European countries: An overview. Eur. J. Cancer 46(17), 3040-3052 (2010
4. I Numeri del Cancro in Italia (Cancer Figures in Italy). Intermedia, Brescia, Italy (2012
5. Mukherji D, Eichholz A, De Bono JS. Management of metastatic castration-resistant prostate cancer: Recent advances. Drugs 72(8), 1011-1028 (2012
6. Rowinsky EK, Calvo E. Novel agents that target tublin and related elements. Semin. Oncol. 33(4), 421-435 (2006
7. Darshan MS, Loftus MS, Thadani-Mulero M et al. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71(18), 6019-6029 (2011
8. Zhu ML, Horbinski CM, Garzotto M, Qian DZ, Beer TM, Kyprianou N. Tubulin-Targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Res. 70(20), 7992-8002 (2010
9. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004
10. Desarnaud F, Geck P, Parkin C, Carpinito G, Makarovskiy AN. Gene expression profiling of the androgen independent prostate cancer cells demonstrates complex mechanisms mediating resistance to docetaxel. Cancer Biol. Ther. 11(2), 204-212 (2011
11. De Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011
12. Petrylak DP. Current clinical trials in castrate-resistant prostate cancer. Curr. Urol. Rep. 12(3), 173-179 (2011
13. Scher HI, Beer TM, Higano CS et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A Phase 1-2 study. Lancet 375(9724), 1437-1446 (2010
14. Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: Pain relief and beyond. Curr. Opin. Support. Palliat. Care 6(3), 310-315 (2012
15. Bissery M-C, Bouchard H, Riou J, Vrignaud P, Combeau C, Bourzat JD. Preclinical evaluation of TXD258, a new taxoid. Presented at: 91st Annual Meeting of the American Association for Cancer Research. San Francisco, CA, USA, 1-5 April 2000
16. Villanueva C, Bazan F, Kim S et al. Cabazitaxel: A novel microtubule inhibitor. Drugs 71(10), 1251-1258 (2011
17. Paller CJ, Antonarakis ES. Cabazitaxel: A novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des. Devel. Ther. 5, 117-124 (2011
18. De Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376(9747), 1147-1154 (2010
19. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for Phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group. J. Clin. Oncol. 17(11), 3461-3467 (1999
20. Bracada S, Di Lorenzo G, Gasparro D et al. Preliminary safety results of an Italian early-Access program (EAP) with cabazitaxel plus prednisone in patients with docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC). Presented at: 48th Annual Meeting of the American Society of Oncology. Chicago, IL, USA, 1-5 June 2012
21. Heidenreich A, Scholz HJ, Rogenhofer S et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: Results from the German compassionate-use programme. Eur. Urol. 63(6), 977-982 (2013
22. Di Lorenzo G, D'Aniello C, Buonerba C et al. PEG-filgrastim and cabazitaxel in prostate cancer patients. Anticancer Drugs 24(1), 84-89 (2012
23. Oudard S, Mercier F, Flechon A et al. Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 31(Suppl. 6), Abstract 137 (2013
24. Angelergues A, Mercier F, Flechon A et al. Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). J. Clin. Oncol. 31(Suppl. 6), Abstract 122 (2013
25. Heidenreich A, Bracarda S, Mason M et al. Tolerability of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer (mCRPC) in Europe. Presented at: European Society for Medical Oncology 2012 Congress. Vienna, Austria, 28 September-2 October 2012
26. Di Lorenzo G, Bracarda S, Buonerba C, Aieta M, Mirone V. Poor survival in prostate cancer patients with primary refractoriness to docetaxel. Eur. Urol. doi:10.1016/j.eururo.2013.10.037 (2013) (Epub ahead of print.